RecruitingNot ApplicableNCT07318129

Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)

Sponsor

Glostrup University Hospital, Copenhagen

Enrollment

220 participants

Start Date

Jan 26, 2026

Study Type

INTERVENTIONAL

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)

Summary

This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a supplement called indole-3-propionic acid (IPA) — a compound naturally produced by gut bacteria — can benefit people with relapsing-remitting multiple sclerosis (RRMS), a form of MS that comes and goes in episodes. **You may be eligible if...** - You are 18 to 65 years old - You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to the 2017 McDonald diagnostic criteria - You are already receiving routine MS treatment and monitoring - You speak and read Danish - You are physically and mentally able to participate **You may NOT be eligible if...** - You have an active cancer - You have Crohn's disease or ulcerative colitis - You are pregnant or breastfeeding - You have had a stem cell transplant - You have a metal implant, pacemaker, or other device incompatible with MRI - You have severe claustrophobia Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTPlacebo

Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Placebo capsules are taken orally.

DIETARY_SUPPLEMENTIndole-3-propionic acid (IPA)

Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Active capsules are taken orally and contain 250 mg of IPA each resulting in a total daily dose of 1000 mg of IPA.